TAFRO Syndrome Without Pathology Supporting Castleman Disease: To Be Treated as iMCD-TAFRO or a Distinct Disease Entity?
iMCD-TAFRO and TAFRO-w/o-iMCD could be considered overlapping entities and these patients should be treated promptly, targeting cytokine storms with similar strategies for each group of patients.
Authors
- Yue Dang (ORCID: https://orcid.org/0009-0000-2166-7515)
- Yuhan Gao (ORCID: https://orcid.org/0000-0002-7249-2855)
- Lu Zhang (ORCID: https://orcid.org/0000-0002-3139-2356)
- Jian Li (ORCID: https://orcid.org/0000-0002-4549-0694)
- Siyuan Li (ORCID: https://orcid.org/0000-0003-1654-3571)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Turkish Journal of Hematology
- Published
- 2025-02-12
- DOI
- https://doi.org/10.4274/tjh.galenos.2025.2024.0420
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00